Jacobs Levy Equity Management
AEGR

Jacobs Levy Equity Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Jacobs Levy Equity Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-155,145
Closed -$574K – 1299
2016
Q1 		$574K Buy
+155,145
New +$961K 0.01% 700

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jacobs Levy Equity Management's AEGR Position: Q2 2016 in Review

Jacobs Levy Equity Management sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 155,145 shares — an estimated $574K sold.

Jacobs Levy Equity Management first reported a position in AEGR in Q1 2016 and held it in 1 quarter. The position peaked at $574K in Q1 2016. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • Jacobs Levy Equity Management reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 155,145 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $574K.
  • Jacobs Levy Equity Management first reported a position in Aegerion Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Aegerion Pharmaceuticals position peaked at $574K in Q1 2016.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2016, filed 15 Aug 2016.